Lipoprotein(a), remnant cholesterol, and high-sensitivity C-reactive protein as complementary biomarkers for myocardial infarction risk assessment
Progress in Cardiovascular Diseases · 2026
DOI: 10.1016/j.pcad.2026.04.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Progress in Cardiovascular Diseases, 2026. Verfasst von Richard Kazibwe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America. Hauptthemen laut MEDLINE: Lipoprotein(a), C-Reactive Protein, Cholesterol, Myocardial Infarction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck, Amgen.
Abstract (Originalsprache)
BACKGROUND: The predictive value of lipoprotein(a) (Lp[a]), high-sensitivity C-reactive protein (hsCRP), and remnant cholesterol (RC) beyond low-density lipoprotein cholesterol (LDL-C) varies across cardiovascular disease (CVD) outcomes. This analysis evaluates the extent to which concentrations of these non-LDL-C biomarkers improve MI-specific risk prediction in a primary prevention population. METHODS: We analyzed 306,183 UK Biobank participants free of cardiovascular disease at baseline with available Lp(a), RC, and hsCRP measurements. RC was calculated as total cholesterol minus LDL-C minus high-density lipoprotein cholesterol (HDL-C). Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression across biomarker quintiles and cumulative biomarker burden. The primary endpoint was the first MI event. RESULTS: Over 15 years of follow-up, 10,824 MI events occurred. In fully adjusted models comparing quintile 5 with quintile 1, HRs (95% CI) were 1.09 (1.08-1.11) for Lp(a), 1.14 (1.13-1.16) for RC, and 1.08 (1.06-1.10) for hsCRP. Per-SD increases were associated with higher MI risk for RC 1.22 (1.20-1.25), Lp(a) 1.16 (1.13-1.18), and hsCRP 1.13 (1.10-1.15). The risk of MI increased stepwise with cumulative biomarker burden; compared with individuals with no biomarker in the top quintile, HRs (95% CI) were 1.45 (1.39-1.51), 2.14 (2.02-2.26), and 2.83 (2.48-3.24) for those with one, two, or all three elevated biomarkers, respectively. CONCLUSIONS: Lp(a), RC, and hsCRP each provide independent and complementary information for MI risk. Their combined elevation identifies individuals at higher MI risk, suggesting selective testing of all three biomarkers in primary prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America.
- Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America.
- Department of Cardiology, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America.
- Department of Cardiology, Brigham and Women's Hospital, Boston, MA, United States of America.
- Center for the Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America. Electronic address: Michael.Shapiro@wfusm.…
Förderung
- Merck
- Amgen
Zitieren
APA
Kazibwe, R., Schaich, C. L., Kingsley, J. A., Chevli, P., Mirzai, S., Rikhi, R., & Shapiro, M. D. (2026). Lipoprotein(a), remnant cholesterol, and high-sensitivity C-reactive protein as complementary biomarkers for myocardial infarction risk assessment. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2026.04.011
Vancouver
Kazibwe R, Schaich CL, Kingsley JA, Chevli P, Mirzai S, Rikhi R, et al. Lipoprotein(a), remnant cholesterol, and high-sensitivity C-reactive protein as complementary biomarkers for myocardial infarction risk assessment. Progress in Cardiovascular Diseases. 2026. doi:10.1016/j.pcad.2026.04.011
BibTeX
@article{Kazibwe2026,
author = {Kazibwe, Richard and Schaich, Christopher L and Kingsley, Jeff A and Chevli, Parag and Mirzai, Saeid and Rikhi, Rishi and Shapiro, Michael D},
title = {Lipoprotein(a), remnant cholesterol, and high-sensitivity C-reactive protein as complementary biomarkers for myocardial infarction risk assessment},
journal = {Progress in Cardiovascular Diseases},
year = {2026},
doi = {10.1016/j.pcad.2026.04.011}
}
EUVIMED